Norroy Bioscience Co. Ltd. has prepared and tested peptide-drug conjugates comprising a fibroblast activation protein α (FAP)-targeting moiety linked to a radionuclide-labeled metal chelating agent for use as positron emission tomography (PET) imaging agents in the diagnosis and/or treatment of cancer.